Name | {(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl}phosphonic acid |
---|---|
Synonyms |
{(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl}phosphonic acid
Phosphonic acid, [(3R)-3-amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]- |
Description | W146 TFA is a selective antagonist of sphingosine-1-phosphate receptor 1 (S1PR1) with an EC50 value of 398 nM. |
---|---|
Related Catalog | |
Target |
EC50: 398 nM (S1PR1)[1]. |
In Vitro | W146 is a S1PR1 antagonist with a Ki of ~70-80 nM[1]. W146 pretreatment significantly increases activated cleaved caspase-3 levels. The reduced EPCs apoptosis which induced by S1P is completely abolished after treatment with W146[2]. Apoptosis Analysis[2] Cell Line: Endothelial progenitor cells (EPCs). Concentration: 10 μM. Incubation Time: 30 min before the addition of S1P. Result: Increases activated cleaved caspase-3 levels. |
In Vivo | W146 (5 mg/kg, ip, prior to AMD3100 administration) pre-treatment shows approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony forming assays, compared to that in mice treated with AMD3100 alone[3] The W146-mediated augmentation of KSL-HSPC mobilization is specific, because pretreatment of mice with W140 is unable to produce any effect on AMD3100-stimulated KSL-HSPC mobilization. Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count in mice[3]. Animal Model: Mice (4-6-week-old)[3] . Dosage: 5 mg/kg. Administration: IP, 1 hour prior to AMD3100 (ADM) administration. Result: Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration. |
References |
Molecular Formula | C18H28F3N2O6P |
---|---|
Molecular Weight | 456.4 |